COMPANY

Belite Bio

HQ: San Diego, CA source · belitebio.com ↗ · West Coast

Keywords: metabolic ophthalmology liver disease diabetes mellitus eye diseases Stargardt Disease 1 STGD1 Geographic Atrophy Tinlarebant BPN-14967

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Timeline

Dec 1, 2025 Raise Follow-on offering: $350M (total, as published), announced Dec 1, 2025. Source: SEC filing. source ↗
Sep 8, 2025 Raise Private placement: $125M (total, as published), announced Sep 8, 2025. Source: SEC filing. source ↗
Aug 6, 2025 Raise Follow-on offering — Registered direct: $15M (total, as published), announced Aug 6, 2025. Source: SEC filing. source ↗
Feb 5, 2025 Raise Follow-on offering — Registered direct: $15M (total, as published), announced Feb 5, 2025. Source: SEC filing. source ↗
Jul 31, 2024 Trial start 2: A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease source ↗
Jul 27, 2023 Trial start 3: Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy source ↗
Mar 28, 2022 Trial start 3: Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease source ↗
Jul 19, 2019 Trial start Phase 1: Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults source ↗

Jun 30, 2027 (ESTIMATED) · 3 · Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy · NCT05949593
2028-02 (ESTIMATED) · 2 · A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease · NCT06388083

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $505.0M. Last 2 years.

Dec 1, 2025 Follow-on offering: $350M (total, as published), announced Dec 1, 2025. Source: SEC filing. source ↗
Sep 8, 2025 Private placement: $125M (total, as published), announced Sep 8, 2025. Source: SEC filing. source ↗
Aug 6, 2025 Follow-on offering — Registered direct: $15M (total, as published), announced Aug 6, 2025. Source: SEC filing. source ↗
Feb 5, 2025 Follow-on offering — Registered direct: $15M (total, as published), announced Feb 5, 2025. Source: SEC filing. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05244304	Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease	3	Completed	Mar 28, 2022	Aug 4, 2025 (actual)
NCT06388083	A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease	2	Active, not recruiting	Jul 31, 2024	2028-02 (estimated)
NCT05949593	Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy	3	Active, not recruiting	Jul 27, 2023	Jun 30, 2027 (estimated)
NCT04005807	Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults	Phase 1	Completed	Jul 19, 2019	Dec 20, 2019 (actual)